BamSEC and AlphaSense Join Forces
Learn More

Cardiovascular Systems Inc.

Formerly NASDAQ: CSII
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 16 pages Product Development Agreement
12/34/56
EX-10.2
from 10-Q 64 pages First Amended and Restated Acquisition Option Agreement by and Among Cardiovascular Systems, Inc. Chansu Vascular Technologies, LLC, and the Members of Chansu Vascular Technologies, LLC, Dated as of December 30, 2022
12/34/56
EX-10.58
from 10-K 6 pages Restricted Stock Agreement Performance-Based Vesting (Total Stockholder Return) Cardiovascular Systems, Inc. 2017 Equity Incentive Plan
12/34/56
EX-10.57
from 10-K 6 pages Restricted Stock Agreement Performance-Based Vesting (Revenue Growth) Cardiovascular Systems, Inc. 2017 Equity Incentive Plan
12/34/56
EX-10.56
from 10-K 5 pages Consulting Agreement
12/34/56
EX-10.55
from 10-K 9 pages June 30, 2022 via Email
12/34/56
EX-10.54
from 10-K 9 pages June 6, 2022 via Email
12/34/56
EX-10.3
from 10-K 1 page Fiscal 2023 Director Compensation Arrangements
12/34/56
EX-10.2
from 10-K 1 page Fiscal 2023 Executive Officer Bonus Plan and Equity Compensation
12/34/56
EX-10.2
from 10-Q 9 pages February 28, 2022 (Revised Per Your Request and Delivered via Email on March 2, 2022) via Email
12/34/56
EX-10.1
from 10-Q 1 page Fiscal 2022 Second Half Bonus Plan
12/34/56
EX-10.2
from 10-Q 3 pages Material contract
12/34/56
EX-10.3
from 10-K 1 page Fiscal 2022 Director Compensation Arrangements
12/34/56
EX-10.2
from 10-K 1 page Fiscal 2022 Executive Officer Bonus Plan and Equity Compensation
12/34/56
EX-10.1
from 10-Q 3 pages Fourth Amendment to Build-To-Suit Lease
12/34/56
EX-10.3
from 10-Q 9 pages Amendment to Purchasing Agreement Agreement No.: Hpg-4037 Vendor: Cardiovascular Systems, Inc. Agreement Date: May 1, 2018 Amendment Date: October 1, 2020
12/34/56
EX-10.2
from 10-Q 2 pages Amendment No. 1 to Product Schedule
12/34/56
EX-10.1
from 10-Q 32 pages Supply Agreement
12/34/56
EX-10.47
from 10-K 8 pages *Certain Information Where Indicated Below in Brackets Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed* June 18, 2020
12/34/56
EX-10.3
from 10-K 1 page Fiscal 2021 Director Compensation Arrangements
12/34/56